Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease-Reference-Cited by-同舟云学术

Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease

Published:2019-10-16 Issue:20 Volume:3 Page:2980-2985
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Bylsma Lauren C.¹^ORCID,Gulbech Ording Anne²,Rosenthal Adam³,Öztürk Buket²,Fryzek Jon P.¹²,Arias Jaime Morales³,Röth Alexander⁴,Berentsen Sigbjørn⁵^ORCID

Affiliation:

1. EpidStrategies, a Division of ToxStrategies, Inc., Rockville, MD;

2. Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark;

3. Sanofi, Waltham, MA;

4. Department of Haematology, University Hospital, University of Duisburg-Essen, Essen, Germany; and

5. Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway

Abstract

Key Points This is the first study to compare thromboembolism and mortality risk in CAD against a general population cohort. Patients with CAD were at a significantly increased risk of death, especially during the first 5 years after diagnosis.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/20/2980/1248649/advancesadv2019000476.pdf

Reference26 articles.

1. How I manage patients with cold agglutinin disease;Berentsen;Br J Haematol,2018

2. Cold agglutinin disease;Swiecicki;Blood,2013

3. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia;Berentsen;Blood Rev,2012

4. Cold agglutinin disease;Berentsen;Hematology Am Soc Hematol Educ Program,2016

5. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins;Shi;Blood,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up;Blood Advances;2023-09-29

2. Complement-directed therapy for cold agglutinin disease: sutimlimab;Expert Review of Hematology;2023-06-02

3. The Histopathology of Cold Agglutinin Disease–Associated B-Cell Lymphoproliferative Disease;American Journal of Clinical Pathology;2023-05-30

4. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease;American Journal of Hematology;2023-05-29

5. Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease;Journal of Pharmacology and Experimental Therapeutics;2023-05-10